NASDAQ:ALNA

Allena Pharmaceuticals Stock Forecast, Price & News

$1.27
-0.03 (-2.31 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.23
$1.30
50-Day Range
$1.08
$1.30
52-Week Range
$1.02
$2.78
Volume836,301 shs
Average Volume1.53 million shs
Market Capitalization$73.27 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16
30 days | 90 days | 365 days | Advanced Chart
Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Allena Pharmaceuticals logo

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

772nd out of 2,100 stocks

Biological Products, Except Diagnostic Industry

110th out of 198 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

Is Allena Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Allena Pharmaceuticals stock.
View analyst ratings for Allena Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Allena Pharmaceuticals?

Wall Street analysts have given Allena Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allena Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Allena Pharmaceuticals
.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) issued its quarterly earnings data on Monday, May, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01.
View Allena Pharmaceuticals' earnings history
.

How has Allena Pharmaceuticals' stock been impacted by COVID-19?

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALNA stock has increased by 0.8% and is now trading at $1.27.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALNA?

5 analysts have issued 1-year price targets for Allena Pharmaceuticals' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 726.8% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 68, Pay $70k)
  • Dr. Louis Brenner, Pres, CEO & Director (Age 51, Pay $823.22k)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 56)
  • Dr. Richard D. Katz, CFO, Principal Financial Officer & Principal Accounting Officer (Age 57)
  • Mr. Geoffrey A. Swire, Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer (Age 49)
  • Mr. Hugh Wight, Sr. VP of Technical Operations
  • Ms. Alicja Januszewicz Ph.D., VP of People & Culture
  • Dr. David J. Clark, Chief Medical Officer (Age 56)
  • Mr. Stephen Yu, Sr. VP of Corp. Quality

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Allena Pharmaceuticals' key competitors?

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (5.20%), Worth Venture Partners LLC (1.70%), Morgan Stanley (1.11%), Renaissance Technologies LLC (0.84%), Geode Capital Management LLC (0.44%) and BlackRock Inc. (0.33%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner.
View institutional ownership trends for Allena Pharmaceuticals
.

Which institutional investors are selling Allena Pharmaceuticals stock?

ALNA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, Millennium Management LLC, and Golden Green Inc.. Company insiders that have sold Allena Pharmaceuticals company stock in the last year include Edward Wholihan, and Louis Md Brenner.
View insider buying and selling activity for Allena Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Allena Pharmaceuticals stock?

ALNA stock was acquired by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, Renaissance Technologies LLC, Geode Capital Management LLC, Bank of New York Mellon Corp, BlackRock Inc., HRT Financial LP, and Harbor Financial Services LLC.
View insider buying and selling activity for Allena Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $1.27.

How much money does Allena Pharmaceuticals make?

Allena Pharmaceuticals has a market capitalization of $73.27 million. The company earns $-32,850,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Allena Pharmaceuticals have?

Allena Pharmaceuticals employs 45 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

Where are Allena Pharmaceuticals' headquarters?

Allena Pharmaceuticals is headquartered at ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.